X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs WOCKHARDT LTD. - Comparison Results

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA WOCKHARDT LTD. ELDER PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x -0.2 -11.0 - View Chart
P/BV x 0.1 2.2 4.6% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 ELDER PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
WOCKHARDT LTD.
Mar-17
ELDER PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs3801,129 33.7%   
Low Rs188627 30.0%   
Sales per share (Unadj.) Rs491.2363.1 135.3%  
Earnings per share (Unadj.) Rs-3.2-20.4 15.6%  
Cash flow per share (Unadj.) Rs14.4-7.0 -206.6%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs376.5301.8 124.7%  
Shares outstanding (eoy) m20.54110.55 18.6%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.62.4 23.9%   
Avg P/E ratio x-89.3-42.9 207.9%  
P/CF ratio (eoy) x19.7-125.9 -15.7%  
Price / Book Value ratio x0.82.9 25.9%  
Dividend payout %0-48.9 0.0%   
Avg Mkt Cap Rs m5,83397,063 6.0%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m2,1799,665 22.5%   
Avg. sales/employee Rs ThNM5,931.8-  
Avg. wages/employee Rs ThNM1,428.1-  
Avg. net profit/employee Rs ThNM-334.0-  
INCOME DATA
Net Sales Rs m10,08940,146 25.1%  
Other income Rs m2571,143 22.5%   
Total revenues Rs m10,34641,289 25.1%   
Gross profit Rs m-792128 -618.7%  
Depreciation Rs m3611,489 24.3%   
Interest Rs m2,7562,253 122.4%   
Profit before tax Rs m-3,653-2,472 147.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125-211 -59.3%   
Profit after tax Rs m-65-2,260 2.9%  
Gross profit margin %-7.80.3 -2,461.8%  
Effective tax rate %-3.48.5 -40.1%   
Net profit margin %-0.6-5.6 11.5%  
BALANCE SHEET DATA
Current assets Rs m9,24046,160 20.0%   
Current liabilities Rs m9,99819,258 51.9%   
Net working cap to sales %-7.567.0 -11.2%  
Current ratio x0.92.4 38.6%  
Inventory Days Days46101 46.0%  
Debtors Days Days6094 63.7%  
Net fixed assets Rs m10,12440,165 25.2%   
Share capital Rs m206553 37.2%   
"Free" reserves Rs m5,58232,814 17.0%   
Net worth Rs m7,73433,367 23.2%   
Long term debt Rs m4,88931,903 15.3%   
Total assets Rs m22,88289,687 25.5%  
Interest coverage x-0.3-0.1 334.9%   
Debt to equity ratio x0.61.0 66.1%  
Sales to assets ratio x0.40.4 98.5%   
Return on assets %11.80 -136,977.7%  
Return on equity %-0.8-6.8 12.5%  
Return on capital %22.3-0.3 -6,655.3%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m3079,121 3.4%   
Fx outflow Rs m1252,133 5.9%   
Net fx Rs m1816,988 2.6%   
CASH FLOW
From Operations Rs m11,754-2,695 -436.2%  
From Investments Rs m-561-6,863 8.2%  
From Financial Activity Rs m-6,76212,545 -53.9%  
Net Cashflow Rs m4,4323,010 147.2%  

Share Holding

Indian Promoters % 39.6 74.5 53.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 2.3 326.1%  
FIIs % 16.8 7.7 218.2%  
ADR/GDR % 0.0 0.1 -  
Free float % 36.1 15.4 234.4%  
Shareholders   16,479 67,757 24.3%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   TORRENT PHARMA  NATCO PHARMA  DIVIS LABORATORIES  PFIZER  ALKEM LABORATORIES  

Compare ELDER PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 219 Points Lower; Energy and Auto Stocks Witness Selling(Closing)

After witnessing volatile trades during the day, Indian share markets ended their session on a negative note. Losses were largely seen in the oil & gas sector, auto sector.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS